Biotie Therapies - Financial Calendar

CHANGE IN THE TIME OF BIOTIE THERAPIES' ANNUAL GENERAL MEETING 2016

BIOTIE THERAPIES CORP.         STOCK  EXCHANGE  RELEASE    4 March 2016, 6.40
p.m.



CHANGE IN THE TIME OF BIOTIE THERAPIES' ANNUAL GENERAL MEETING 2016

Due to the announced tender offer by Acorda Therapeutics, Inc. to purchase all
of the issued and outstanding shares, American Depositary Shares, stock options,
share units and warrants in Biotie Therapies Corp. ("Biotie" or the "Company")
the date of the Annual General Meeting of Biotie will change from the previously
announced 20 April 2016. The Annual General Meeting will be held no later than
30 June 2016 at a date to be announced later at the end of the tender offer
period. The notice of the Annual General Meeting will be delivered to
shareholders no later than three weeks before the Annual General Meeting.

As announced on 3 March 2016, the draft tender offer document to be released in
connection with the Tender Offer has been filed for approval with the Finnish
Financial Supervisory Authority and currently, the offer period is expected to
commence by mid-March 2016.


Turku, March 4, 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie  is  a  specialized  drug  development  company  focused  on products for
neurodegenerative  and psychiatric disorders. Biotie's development has delivered
Selincro  (nalmefene) for alcohol dependence,  which received European marketing
authorization  in 2013 and is currently being  marketed across Europe by partner
Lundbeck.  The current  development products  include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional compounds which are
in  Phase 2 development  for cognitive  disorders including  Parkinson's disease
dementia,  and primary sclerosing cholangitis (PSC),  a rare fibrotic disease of
the liver.

INFORMATION REGARDING ACORDA

Founded  in  1995, Acorda  is  a  biotechnology  company  focused  on developing
therapies that improve the lives of people with neurological disorders, with its
common stock listed on Nasdaq US.

Acorda  has  an  industry  leading  pipeline  of  novel  neurological  therapies
addressing  a  range  of  disorders,  including  multiple sclerosis, Parkinson's
disease,  post-stroke walking  deficits, epilepsy  and migraine.  Acorda markets
three  FDA-approved therapies, including AMPYRA (dalfampridine) Extended Release
Tablets, 10 mg.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

SOME OF THE STATEMENTS CONTAINED IN THIS RELEASE ARE FORWARD-LOOKING STATEMENTS,
INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE ACQUISITION,
WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING THE SATISFACTION
OF CLOSING CONDITIONS FOR THE ACQUISITION, SUCH AS TENDER OF AT LEAST 90% OF THE
OUTSTANDING SHARES AND VOTING RIGHTS OF THE COMPANY, THE POSSIBILITY THAT THE
TRANSACTION WILL NOT BE COMPLETED AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN
THE COMPANY'S PUBLIC FILINGS WITH THE SEC, INCLUDING THE "RISK FACTORS" SECTION
OF THE COMPANY'S REGISTRATION STATEMENT ON FORM F-1 (NO. 333-204147), AS WELL AS
THE TENDER OFFER DOCUMENTS TO BE FILED BY ACORDA AND THE
SOLICITATION/RECOMMENDATION STATEMENT TO BE FILED BY THE COMPANY.  THESE
STATEMENTS ARE BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND
PROJECTIONS, AND INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER
FACTORS THAT MAY CAUSE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS
TO BE MATERIALLY DIFFERENT FROM ANY FUTURE STATEMENTS.  THESE STATEMENTS ARE
GENERALLY IDENTIFIED BY WORDS OR PHRASES SUCH AS "BELIEVE", "ANTICIPATE",
"EXPECT", "INTEND", "PLAN", "WILL", "MAY", "SHOULD", "ESTIMATE", "PREDICT",
"POTENTIAL", "CONTINUE" OR THE NEGATIVE OF SUCH TERMS OR OTHER SIMILAR
EXPRESSIONS.  IF UNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS OR
UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTS MAY DIFFER
MATERIALLY FROM THE EXPECTED RESULTS AND/OR TIMING DISCUSSED IN THE FORWARD-
LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE
STATEMENTS.  THE COMPANY DISCLAIMS ANY INTENT OR OBLIGATION TO UPDATE ANY
FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE
PERIOD COVERED BY THIS RELEASE OR OTHERWISE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

THE OFFER HAS NOT BEEN COMMENCED.  THIS RELEASE IS FOR INFORMATIONAL PURPOSES
ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER
TO SELL COMPANY SECURITIES.  THE SOLICITATION AND OFFER TO BUY COMPANY
SECURITIES WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED
MATERIALS.  AT THE TIME THE OFFER IS COMMENCED, ACORDA WILL FILE A TENDER OFFER
STATEMENT ON SCHEDULE TO WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE
"SEC") AND THEREAFTER, THE COMPANY WILL FILE A SOLICITATION/RECOMMENDATION
STATEMENT ON SCHEDULE 14D-9 WITH RESPECT TO THE OFFER.  INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ THESE MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE
SINCE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND
CONDITIONS OF THE OFFER.  THE OFFER TO PURCHASE, SOLICITATION/RECOMMENDATION
STATEMENT AND RELATED MATERIALS WILL BE FILED BY ACORDA AND THE COMPANY WITH THE
SEC, AND INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THESE
MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED BY ACORDA AND THE COMPANY
WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW.SEC.GOV.  INVESTORS AND
SECURITY HOLDERS MAY ALSO OBTAIN FREE COPIES OF THE SOLICITATION/RECOMMENDATION
STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC BY THE COMPANY AT
WWW.BIOTIE.COM.




[HUG#1992004]